Inspections, Compliance, Enforcement, and Criminal Investigations
Christus Coushatta Health Care Center 22-Jun-01
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
| Food
and Drug Administration New Orleans District Southeast Region 6600 Plaza Drive, Suite 400 New Orleans, LA 70127-2601 Telephone: 504-253-4519 FAX: 504-253-4520 |
June 22, 2001
WARNING LETTER NO. 2001 -NOL-31
FEDERAL EXPRESS
OVERNIGHT DELIVERY
Sister Laureen Painter,
CEO
Christus Coushatta Health Care Center
1635 Marvel Street
Coushatta, Louisiana 71019
Dear Sister Painter:
We are writing to you because on June 5,2001, your facility was inspected by a representative of the State of Louisiana, acting on behalf of the U.S. Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving mammography at your facility.
Under a United States Federal Law, the Mammography Quality Standards Act (MQSA) of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1 finding at your facility:
- Phantom quality control records
were missing for at least 4 weeks for unit 1, Lorad
Medical Systems Inc.
The specific problem noted above appeared on your MQSA Facility Inspection Report,
which was issued to your facility at the close of the inspection. This problem
has been identified as Level 1, because it identifies a failure to meet a significant
MQSA requirement.
It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:
- the specific steps you have taken to correct the violation noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations; and,
- include sample records that demonstrate
proper record keeping procedures, if the findings
relate to quality control (Phantom QC, Processor QC).
Please submit your response to:
Rebecca A. Asente, Compliance Officer
U.S. Food and Drug Administration
6600 Plaza Drive, Suite 400
New Orleans, Louisiana 70127-2601
Telephone: (504) 253-4519
Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDAs requirements for mammography facilities by contacting the Mammography Quality Assurance Program, U. S. Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http: //www .fda.gov.
If you have more specific questions about mammography facility requirements, or about the contents of this letter, please feel flee to contact Stacy G. Marshall at (504) 253-4554.
Sincerely,
/s/
Patricia K. Schafer
Acting District Director
New Orleans District Office
cc:
Priscilla F. Butler, M.S.
Director, Breast Imaging Accreditation Programs
American College of Radiology
1891 Preston White Drive
Reston, Virginia 22091Jim Potter, Director
Government Relations
c/o American College of Radiology
1891 Preston White Drive
Reston, Virginia 22091-







